Understand the source comparison
Peptides for Female Infertility Protocol Evidence Guide: Clinical Trial Comparison
Before adopting any peptide protocol, clinicians need to understand which compounds have randomised controlled trial evidence versus case series or mechanistic studies only. The table below compares the four most commonly referenced reproductive peptides. Kiss
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before adopting any peptide protocol, clinicians need to understand which compounds have randomised controlled trial evidence versus case series or mechanistic studies only. The table below compares the four most commonly referenced reproductive peptides.
- Kisspeptin-54
- GPR54 receptor activation → GnRH pulsatile release
- Phase 2 RCT, 53 women with HA (JCEM 2018)
- 87% ovulation rate vs 0% placebo
- Injection site reaction (mild), no OHSS
- Strongest evidence for anovulatory infertility; mechanism bypasses pituitary dysfunction
- Follistatin-288
- Activin neutralisation → enhanced decidualisation
- Pilot study, 18 RIF patients (Fertil Steril 2019)
- 67% pregnancy within 2 cycles
- Transient joint stiffness (8% of subjects)
- Promising for implantation failure; needs Phase 2 replication
- Thymosin Beta-4
- Treg upregulation → NK cell suppression
- Cohort study, 32 RPL patients (Am J Reprod Immunol 2017)
- 62.5% live birth vs 28% controls
- Headache (12%), fatigue (9%)
- Mechanistically sound but lacks RCT validation; cost advantage over IVIG
- GnRH Analogues (Leuprolide)
- GnRH receptor desensitisation → FSH surge suppression
- Multiple Phase 3 trials in IVF protocols
- N/A (used to prevent premature ovulation)
- Hot flashes (40%), mood changes (18%)
- FDA-approved for IVF cycle control; not ovulation-inducing
- The bottom line: only kisspeptin has Phase 2 randomised controlled trial evidence for ovulation induction. Follistatin and Tβ4 remain in the pilot-study phase—efficacy signals are present, but statistical power is limited. GnRH analogues are included for context because patients often confuse them with GnRH agonists—they suppress ovulation rather than induce it.